8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 4, 2026·SEC
AbbVie Inc.(ABBV)Earnings, Financials & Key Ratios
ABBV•NYSE
$206.15
$364.63B mkt cap·87.0× P/E·Price updated May 6, 2026
AboutAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Show more
- Revenue$61.16B+8.6%
- EBITDA$28.23B+61.1%
- Net Income$4.23B-1.2%
- EPS (Diluted)2.37-0.8%
- Gross Margin70.24%+0.3%
- EBITDA Margin46.16%+48.4%
- Operating Margin32.85%+102.5%
- Net Margin6.91%-9.0%
- ROE6214.71%+9895.4%
- ROIC23.86%+114.8%
- Interest Coverage3.28+41.2%
ABBV Key Insights
AbbVie Inc. (ABBV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 2104.0%
- ✓FCF machine: 29.1% free cash flow margin
- ✓13 consecutive years of dividend growth
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 3.2%
- ✓Healthy 5Y average net margin of 12.9%
✗Weaknesses
- ✗Dividend payout exceeds 100% of earnings
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ABBV Price & Volume
AbbVie Inc. (ABBV) stock price & volume — 10-year historical chart
Loading chart...
ABBV Growth Metrics
AbbVie Inc. (ABBV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years10.34%
5 Years5.95%
3 Years1.75%
TTM8.57%
Profit CAGR
10 Years-1.95%
5 Years-1.75%
3 Years-29.06%
TTM-1.22%
EPS CAGR
10 Years-2.74%
5 Years-2.72%
3 Years-29.03%
TTM-1.36%
Return on Capital
10 Years15.87%
5 Years15.02%
3 Years14.44%
Last Year21.48%
ABBV Recent Earnings
AbbVie Inc. (ABBV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 12/12 qtrs (100%)
Q2 2026Latest
Apr 29, 2026EPS
$2.65
Est $2.59
+2.3%
Revenue
$15.0B
Est $14.7B
+1.9%
Q1 2026
Feb 4, 2026EPS
$2.71
Est $2.65
+2.3%
Revenue
$16.6B
Est $16.4B
+1.2%
Q4 2025
Oct 31, 2025EPS
$1.86
Est $1.77
+5.1%
Revenue
$15.8B
Est $15.6B
+1.2%
Q3 2025
Jul 31, 2025EPS
$2.97
Est $2.88
+3.1%
Revenue
$15.4B
Est $15.0B
+2.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $2.65vs $2.59+2.3% | $15.0Bvs $14.7B+1.9% |
| Q1 2026 | Feb 4, 2026 | $2.71vs $2.65+2.3% | $16.6Bvs $16.4B+1.2% |
| Q4 2025 | Oct 31, 2025 | $1.86vs $1.77+5.1% | $15.8Bvs $15.6B+1.2% |
| Q3 2025 | Jul 31, 2025 | $2.97vs $2.88+3.1% | $15.4Bvs $15.0B+2.6% |
Based on last 12 quarters of dataView full earnings history →
ABBV Peer Comparison
AbbVie Inc. (ABBV) competitors in Specialty and biologics-focused pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 JNJ | 543.64B | 225.59 | 38.96 | 4.3% | 27.26% | 31.69% | 3.65% | 0.51 |
 MRK | 279.49B | 113.16 | 15.54 | 1.18% | 28.12% | 36.14% | 4.42% | 0.96 |
 PFE | 150.4B | 26.44 | 19.44 | -1.65% | 11.83% | 8.34% | 6.03% | 0.78 |
 BMY | 116.22B | 56.92 | 16.50 | -0.22% | 15.01% | 38.96% | 11.05% | 2.55 |
 LLY | 933.66B | 988.19 | 43.06 | 44.7% | 34.98% | 101.17% | 0.96% | 1.60 |
 AMGN | 177.87B | 329.59 | 23.16 | 9.92% | 20.95% | 89.41% | 4.55% | 6.31 |
 GILD | 166.32B | 133.48 | 351.26 | 6.04% | 28.9% | 37.62% | 6.2% | 1.39 |
 BIIB | 27.92B | 189.13 | 21.42 | 1.39% | 13.92% | 7.55% | 7.34% | 0.38 |
Compare ABBV vs Peers
AbbVie Inc. (ABBV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABBV Income Statement
AbbVie Inc. (ABBV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 28.22B | 32.75B | 33.27B | 45.8B | 56.2B | 58.05B | 54.32B | 56.33B | 61.16B |
| Revenue Growth % | 10.06% | 16.08% | 1.57% | 37.69% | 22.69% | 3.3% | -6.44% | 3.71% | 8.57% |
| Cost of Goods Sold | 7.04B | 7.72B | 7.44B | 15.39B | 17.45B | 17.41B | 20.41B | 16.9B | 18.2B |
| COGS % of Revenue | 24.95% | 23.56% | 22.36% | 33.59% | 31.04% | 30% | 37.58% | 30.01% | 29.76% |
| Gross Profit | 21.18B▲ 0% | 25.04B▲ 18.2% | 25.83B▲ 3.2% | 30.42B▲ 17.8% | 38.75B▲ 27.4% | 40.64B▲ 4.9% | 33.9B▼ 16.6% | 39.43B▲ 16.3% | 42.96B▲ 8.9% |
| Gross Margin % | 75.05% | 76.44% | 77.64% | 66.41% | 68.96% | 70% | 62.42% | 69.99% | 70.24% |
| Gross Profit Growth % | 6.92% | 18.22% | 3.16% | 17.77% | 27.4% | 4.87% | -16.58% | 16.3% | 8.94% |
| Operating Expenses | 11.63B | 18.65B | 12.84B | 19.05B | 20.83B | 22.52B | 21.15B | 30.29B | 22.86B |
| OpEx % of Revenue | 41.21% | 56.95% | 38.61% | 41.6% | 37.06% | 38.8% | 38.93% | 53.77% | 37.39% |
| Selling, General & Admin | 6.29B | 7.4B | 6.94B | 11.3B | 12.35B | 15.26B | 12.87B | 14.75B | 14.01B |
| SG&A % of Revenue | 22.31% | 22.59% | 20.87% | 24.67% | 21.97% | 26.29% | 23.7% | 26.19% | 22.91% |
| Research & Development | 5.33B | 10.75B | 6.79B | 7.75B | 8.05B | 6.51B | 7.67B | 12.79B | 9.1B |
| R&D % of Revenue | 18.9% | 32.83% | 20.42% | 16.93% | 14.32% | 11.21% | 14.13% | 22.71% | 14.87% |
| Other Operating Expenses | 0 | 500M | -890M | 0 | 432M | 753M | 599M | 2.75B | -241M |
| Operating Income | 9.54B▲ 0% | 6.38B▼ 33.1% | 12.98B▲ 103.4% | 11.36B▼ 12.5% | 17.92B▲ 57.7% | 18.12B▲ 1.1% | 12.76B▼ 29.6% | 9.14B▼ 28.4% | 20.09B▲ 119.9% |
| Operating Margin % | 33.83% | 19.49% | 39.03% | 24.81% | 31.89% | 31.21% | 23.49% | 16.22% | 32.85% |
| Operating Income Growth % | 2.19% | -33.13% | 103.4% | -12.48% | 57.74% | 1.08% | -29.59% | -28.38% | 119.89% |
| EBITDA | 11.05B | 8.15B | 15B | 17.83B | 26.45B | 26.58B | 21.45B | 17.52B | 28.23B |
| EBITDA Margin % | 39.15% | 24.88% | 45.09% | 38.94% | 47.06% | 45.79% | 39.5% | 31.11% | 46.16% |
| EBITDA Growth % | 4.91% | -26.24% | 84.09% | 18.89% | 48.28% | 0.53% | -19.29% | -18.33% | 61.1% |
| D&A (Non-Cash Add-back) | 1.5B | 1.76B | 2.02B | 6.47B | 8.52B | 8.47B | 8.7B | 8.39B | 8.14B |
| EBIT | 8.88B | 6.54B | 10.21B | 5.85B | 15.41B | 15.71B | 8.47B | 6.52B | 9.49B |
| Net Interest Income | -1B | -1.14B | -1.51B | -2.28B | -2.38B | -2.04B | -1.68B | -2.16B | -2.63B |
| Interest Income | 146M | 204M | 275M | 174M | 39M | 186M | 540M | 648M | 266M |
| Interest Expense | 1.15B | 1.35B | 1.78B | 2.45B | 2.42B | 2.23B | 2.22B | 2.81B | 2.89B |
| Other Income/Expense | -1.82B | -1.19B | -4.56B | -7.96B | -4.93B | -4.64B | -6.51B | -5.42B | -13.49B |
| Pretax Income | 7.73B▲ 0% | 5.2B▼ 32.7% | 8.43B▲ 62.1% | 3.4B▼ 59.7% | 12.99B▲ 282.3% | 13.48B▲ 3.8% | 6.25B▼ 53.6% | 3.72B▼ 40.5% | 6.6B▲ 77.5% |
| Pretax Margin % | 27.39% | 15.87% | 25.33% | 7.42% | 23.11% | 23.21% | 11.51% | 6.6% | 10.79% |
| Income Tax | 2.42B | -490M | 544M | -1.22B | 1.44B | 1.63B | 1.38B | -570M | 2.36B |
| Effective Tax Rate % | 31.29% | -9.43% | 6.46% | -36.02% | 11.09% | 12.11% | 22.03% | -15.34% | 35.83% |
| Net Income | 5.31B▲ 0% | 5.69B▲ 7.1% | 7.88B▲ 38.6% | 4.62B▼ 41.4% | 11.54B▲ 150.0% | 11.84B▲ 2.5% | 4.86B▼ 58.9% | 4.28B▼ 12.0% | 4.23B▼ 1.2% |
| Net Margin % | 18.82% | 17.36% | 23.69% | 10.08% | 20.54% | 20.39% | 8.95% | 7.59% | 6.91% |
| Net Income Growth % | -10.82% | 7.12% | 38.6% | -41.44% | 150.04% | 2.55% | -58.91% | -12.03% | -1.22% |
| Net Income (Continuing) | 5.31B | 5.69B | 7.88B | 4.62B | 11.55B | 11.85B | 4.87B | 4.29B | 4.23B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 21M | 28M | 33M | 37M | 39M | 42M |
| EPS (Diluted) | 3.30▲ 0% | 3.68▲ 11.5% | 5.28▲ 43.5% | 2.72▼ 48.5% | 6.45▲ 137.1% | 6.63▲ 2.8% | 2.72▼ 59.0% | 2.39▼ 12.1% | 2.37▼ 0.8% |
| EPS Growth % | -9.09% | 11.52% | 43.48% | -48.48% | 137.13% | 2.79% | -58.97% | -12.13% | -0.84% |
| EPS (Basic) | 3.31 | 3.69 | 5.30 | 2.73 | 6.48 | 6.65 | 2.73 | 2.40 | 2.37 |
| Diluted Shares Outstanding | 1.6B | 1.55B | 1.48B | 1.67B | 1.78B | 1.78B | 1.77B | 1.77B | 1.77B |
| Basic Shares Outstanding | 1.6B | 1.54B | 1.48B | 1.67B | 1.77B | 1.77B | 1.77B | 1.77B | 1.78B |
| Dividend Payout Ratio | 77.36% | 98.12% | 80.77% | 167.16% | 80.24% | 84.85% | 216.72% | 257.71% | 275.84% |
ABBV Balance Sheet
AbbVie Inc. (ABBV) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 21.22B | 16.95B | 49.52B | 24.17B | 27.93B | 28.46B | 33B | 25.58B | 29.06B |
| Cash & Short-Term Investments | 9.79B | 8.06B | 39.92B | 8.48B | 9.83B | 9.23B | 12.82B | 5.55B | 5.26B |
| Cash Only | 9.3B | 7.29B | 39.92B | 8.45B | 9.75B | 9.2B | 12.81B | 5.52B | 5.23B |
| Short-Term Investments | 486M | 772M | 0 | 30M | 84M | 28M | 2M | 31M | 28M |
| Accounts Receivable | 5.09B | 5.38B | 5.43B | 8.82B | 9.98B | 11.25B | 11.15B | 10.92B | 12.59B |
| Days Sales Outstanding | 65.82 | 60 | 59.56 | 70.3 | 64.8 | 70.76 | 74.96 | 70.75 | 75.13 |
| Inventory | 1.6B | 1.6B | 1.81B | 3.31B | 3.13B | 3.58B | 4.1B | 4.18B | 4.95B |
| Days Inventory Outstanding | 83.21 | 75.9 | 88.96 | 78.52 | 65.44 | 75.02 | 73.29 | 90.28 | 99.27 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 4.4B | 4.93B | 4.93B | 6.26B |
| Total Non-Current Assets | 49.56B | 42.41B | 39.6B | 126.39B | 118.6B | 110.34B | 101.71B | 109.58B | 104.9B |
| Property, Plant & Equipment | 2.8B | 2.88B | 2.96B | 5.25B | 5.11B | 4.93B | 4.99B | 5.13B | 6.37B |
| Fixed Asset Turnover | 10.07x | 11.36x | 11.23x | 8.73x | 11.00x | 11.76x | 10.89x | 10.97x | 9.61x |
| Goodwill | 15.79B | 15.66B | 15.6B | 33.12B | 32.38B | 32.16B | 32.29B | 34.96B | 35.64B |
| Intangible Assets | 27.56B | 21.23B | 18.65B | 82.88B | 75.95B | 67.44B | 55.61B | 60.07B | 52.64B |
| Long-Term Investments | 2.09B | 1.42B | 93M | 293M | 277M | 241M | 304M | 279M | 299M |
| Other Non-Current Assets | 1.33B | 1.21B | 2.29B | 4.85B | 4.88B | 5.57B | 8.51B | 9.14B | 9.95B |
| Total Assets | 70.79B▲ 0% | 59.35B▼ 16.2% | 89.11B▲ 50.1% | 150.56B▲ 69.0% | 146.53B▼ 2.7% | 138.81B▼ 5.3% | 134.71B▼ 2.9% | 135.16B▲ 0.3% | 133.96B▼ 0.9% |
| Asset Turnover | 0.40x | 0.55x | 0.37x | 0.30x | 0.38x | 0.42x | 0.40x | 0.42x | 0.46x |
| Asset Growth % | 7.09% | -16.15% | 50.15% | 68.96% | -2.68% | -5.27% | -2.95% | 0.33% | -0.89% |
| Total Current Liabilities | 16.64B | 17.24B | 15.59B | 28.66B | 35.19B | 29.54B | 37.84B | 38.75B | 43.29B |
| Accounts Payable | 1.47B | 1.55B | 1.45B | 2.28B | 2.88B | 2.93B | 3.69B | 2.94B | 3.59B |
| Days Payables Outstanding | 76.42 | 73.11 | 71.24 | 53.99 | 60.3 | 61.5 | 65.94 | 63.59 | 72.02 |
| Short-Term Debt | 6.42B | 5.31B | 3.75B | 8.68B | 12.67B | 4.3B | 7.19B | 6.8B | 8.75B |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.14B | 1.61B | 0 | 16.04B | 17.85B | 20.93B | 25.16B | 27.01B | 25.63B |
| Current Ratio | 1.28x | 0.98x | 3.18x | 0.84x | 0.79x | 0.96x | 0.87x | 0.66x | 0.67x |
| Quick Ratio | 1.18x | 0.89x | 3.06x | 0.73x | 0.70x | 0.84x | 0.76x | 0.55x | 0.56x |
| Cash Conversion Cycle | 72.61 | 62.79 | 77.27 | 94.83 | 69.95 | 84.28 | 82.31 | 97.43 | 102.38 |
| Total Non-Current Liabilities | 49.05B | 50.56B | 81.7B | 108.81B | 95.9B | 91.98B | 86.47B | 93.05B | 93.9B |
| Long-Term Debt | 30.95B | 35B | 62.98B | 77.53B | 64.16B | 59.12B | 52.17B | 60.34B | 59.61B |
| Capital Lease Obligations | 0 | 0 | 271M | 853M | 738M | 771M | 762M | 720M | 711M |
| Deferred Tax Liabilities | 5.17B | 3.79B | 3.9B | 9.33B | 8.98B | 8.69B | 8.63B | 7.63B | 7.96B |
| Other Non-Current Liabilities | 12.92B | 11.76B | 14.57B | 21.09B | 22.02B | 23.4B | 24.91B | 24.38B | 25.62B |
| Total Liabilities | 65.69B | 67.8B | 97.29B | 137.47B | 131.09B | 121.52B | 124.31B | 131.8B | 137.19B |
| Total Debt | 37.37B | 40.31B | 67.09B | 87.06B | 77.58B | 64.19B | 60.12B | 67.84B | 69.07B |
| Net Debt | 28.07B | 33.02B | 27.16B | 78.61B | 67.83B | 54.99B | 47.31B | 62.32B | 63.84B |
| Debt / Equity | 7.33x | - | - | 6.65x | 5.03x | 3.71x | 5.78x | 20.17x | - |
| Debt / EBITDA | 3.38x | 4.95x | 4.47x | 4.88x | 2.93x | 2.41x | 2.80x | 3.87x | 2.45x |
| Net Debt / EBITDA | 2.54x | 4.05x | 1.81x | 4.41x | 2.56x | 2.07x | 2.20x | 3.56x | 2.26x |
| Interest Coverage | 7.72x | 4.86x | 5.72x | 2.38x | 6.36x | 7.04x | 3.81x | 2.32x | 3.28x |
| Total Equity | 5.1B▲ 0% | -8.45B▼ 265.7% | -8.17B▲ 3.2% | 13.1B▲ 260.3% | 15.44B▲ 17.9% | 17.29B▲ 12.0% | 10.4B▼ 39.9% | 3.36B▼ 67.6% | -3.23B▼ 196.0% |
| Equity Growth % | 9.94% | -265.71% | 3.24% | 260.27% | 17.86% | 11.99% | -39.86% | -67.64% | -195.96% |
| Book Value per Share | 3.18 | -5.46 | -5.51 | 7.83 | 8.69 | 9.72 | 5.86 | 1.90 | -1.82 |
| Total Shareholders' Equity | 5.1B | -8.45B | -8.17B | 13.08B | 15.41B | 17.25B | 10.36B | 3.33B | -3.27B |
| Common Stock | 18M | 18M | 18M | 18M | 18M | 18M | 18M | 18M | 18M |
| Retained Earnings | 5.46B | 3.37B | 4.72B | 1.05B | 3.13B | 4.78B | -1B | -7.9B | -15.49B |
| Treasury Stock | -11.92B | -24.11B | -24.5B | -2.26B | -3.14B | -4.59B | -6.53B | -8.2B | -9.15B |
| Accumulated OCI | -2.73B | -2.48B | -3.6B | -3.12B | -2.9B | -2.2B | -2.31B | -1.93B | -1.14B |
| Minority Interest | 0 | 0 | 0 | 21M | 28M | 33M | 37M | 39M | 42M |
ABBV Cash Flow Statement
AbbVie Inc. (ABBV) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 9.96B | 13.43B | 13.32B | 17.59B | 22.78B | 24.94B | 22.84B | 18.81B | 19.03B |
| Operating CF Margin % | 35.3% | 40.99% | 40.05% | 38.4% | 40.53% | 42.97% | 42.05% | 33.38% | 31.12% |
| Operating CF Growth % | 41.46% | 34.81% | -0.77% | 32% | 29.5% | 9.51% | -8.44% | -17.66% | 1.19% |
| Net Income | 5.31B | 5.69B | 7.88B | 4.62B | 11.55B | 11.85B | 4.82B | 4.29B | 4.23B |
| Depreciation & Amortization | 1.5B | 1.76B | 2.02B | 6.47B | 8.52B | 8.47B | 8.7B | 8.39B | 8.14B |
| Stock-Based Compensation | 365M | 421M | 430M | 753M | 692M | 671M | 747M | 911M | 955M |
| Deferred Taxes | 1.24B | 424M | 700M | -2.33B | -898M | -1.93B | -2.89B | -1.45B | -492M |
| Other Non-Cash Items | 1.53B | 6.26B | 3.62B | 7.96B | 4.24B | 6.15B | 8.65B | 9.45B | 8.6B |
| Working Capital Changes | 9M | -1.13B | -1.33B | 106M | -1.32B | -258M | 2.81B | -2.78B | -2.36B |
| Change in Receivables | -391M | -591M | -74M | -929M | -1.32B | -1.46B | 66M | 207M | -1.49B |
| Change in Inventory | 93M | -226M | -231M | -40M | -142M | -686M | -417M | -319M | -234M |
| Change in Payables | 425M | 190M | -1.12B | 1.51B | 1.63B | 1.6B | 3.84B | 177M | 951M |
| Cash from Investing | -274M | -1.01B | 596M | -37.56B | -2.34B | -623M | -2.01B | -20.82B | -6.64B |
| Capital Expenditures | -529M | -638M | -552M | -798M | -787M | -695M | -777M | -974M | -1.21B |
| CapEx % of Revenue | 1.87% | 1.95% | 1.66% | 1.74% | 1.4% | 1.2% | 1.43% | 1.73% | 1.98% |
| Acquisitions | -308M | -736M | -1.14B | -39.61B | -1.9B | -794M | -1.22B | -17.49B | -204M |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 167M | 1.39B | 366M | 774M | 13M | -2.83B | -5.27B |
| Cash from Financing | -5.51B | -14.4B | 18.71B | -11.5B | -19.04B | -24.8B | -17.22B | -5.21B | -12.72B |
| Debt Issued (Net) | -2M | 3.23B | 26.25B | -2.68B | -8.41B | -12.43B | -4.15B | 7.35B | -327M |
| Equity Issued (Net) | -1.41B | -12.01B | -629M | -978M | -934M | -1.49B | -1.97B | -1.71B | -808M |
| Dividends Paid | -4.11B | -5.58B | -6.37B | -7.72B | -9.26B | -10.04B | -10.54B | -11.03B | -11.66B |
| Share Repurchases | -1.41B | -12.01B | -629M | -978M | -934M | -1.49B | -1.97B | -1.71B | -980M |
| Other Financing | 30M | -31M | -544M | -124M | -430M | -840M | -562M | 172M | 68M |
| Net Change in Cash | 4.2B▲ 0% | -2.01B▼ 147.9% | 32.63B▲ 1720.4% | -31.48B▼ 196.4% | 1.3B▲ 104.1% | -545M▼ 142.0% | 3.61B▲ 762.9% | -7.29B▼ 301.8% | -295M▲ 96.0% |
| Free Cash Flow | 9.43B▲ 0% | 12.79B▲ 35.6% | 12.77B▼ 0.1% | 16.79B▲ 31.5% | 21.99B▲ 31.0% | 24.25B▲ 10.3% | 22.06B▼ 9.0% | 17.83B▼ 19.2% | 17.82B▼ 0.1% |
| FCF Margin % | 33.42% | 39.05% | 38.39% | 36.66% | 39.13% | 41.77% | 40.62% | 31.65% | 29.13% |
| FCF Growth % | 43.72% | 35.61% | -0.13% | 31.46% | 30.97% | 10.27% | -9.02% | -19.17% | -0.09% |
| FCF per Share | 5.88 | 8.27 | 8.61 | 10.04 | 12.37 | 13.64 | 12.44 | 10.06 | 10.04 |
| FCF Conversion (FCF/Net Income) | 1.88x | 2.36x | 1.69x | 3.81x | 1.97x | 2.11x | 4.70x | 4.40x | 4.50x |
| Interest Paid | 1.1B | 1.22B | 1.79B | 2.62B | 2.71B | 2.55B | 2.47B | 2.81B | 0 |
| Taxes Paid | 1.7B | -35M | 1.45B | 1.67B | 3.65B | 2.99B | 4.7B | 4.06B | 0 |
ABBV Key Ratios
AbbVie Inc. (ABBV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 138.75% | 109.09% | - | - | 187.45% | 80.9% | 72.34% | 35.13% | 62.18% | 6214.71% |
| Return on Invested Capital (ROIC) | 22.03% | 20.59% | 16.58% | 44.7% | 15.4% | 15.37% | 17.47% | 14.72% | 11.11% | 23.86% |
| Gross Margin | 77.25% | 75.05% | 76.44% | 77.64% | 66.41% | 68.96% | 70% | 62.42% | 69.99% | 70.24% |
| Net Margin | 23.22% | 18.82% | 17.36% | 23.69% | 10.08% | 20.54% | 20.39% | 8.95% | 7.59% | 6.91% |
| Debt / Equity | 7.95x | 7.33x | - | - | 6.65x | 5.03x | 3.71x | 5.78x | 20.17x | - |
| Interest Coverage | 8.53x | 7.72x | 4.86x | 5.72x | 2.38x | 6.36x | 7.04x | 3.81x | 2.32x | 3.28x |
| FCF Conversion | 1.18x | 1.88x | 2.36x | 1.69x | 3.81x | 1.97x | 2.11x | 4.70x | 4.40x | 4.50x |
| Revenue Growth | 12.16% | 10.06% | 16.08% | 1.57% | 37.69% | 22.69% | 3.3% | -6.44% | 3.71% | 8.57% |
ABBV SEC Filings & Documents
AbbVie Inc. (ABBV) SEC filings — annual & quarterly reports (10-K, 10-Q)
ABBV Frequently Asked Questions
AbbVie Inc. (ABBV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
AbbVie Inc. (ABBV) reported $61.16B in revenue for fiscal year 2025. This represents a 291% increase from $15.64B in 2010.
AbbVie Inc. (ABBV) grew revenue by 8.6% over the past year. This is steady growth.
Yes, AbbVie Inc. (ABBV) is profitable, generating $4.23B in net income for fiscal year 2025 (6.9% net margin).
Dividend & Returns
Yes, AbbVie Inc. (ABBV) pays a dividend with a yield of 3.19%. This makes it attractive for income-focused investors.
AbbVie Inc. (ABBV) has a return on equity (ROE) of 6214.7%. This is excellent, indicating efficient use of shareholder capital.
AbbVie Inc. (ABBV) generated $18.70B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More ABBV
AbbVie Inc. (ABBV) financial analysis — history, returns, DCA and operating performance tools
Full ABBV Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates